Aelis Farma: Availability of the 2022 half-year financial report


BORDEAUX, France–(BUSINESS WIRE)–Regulatory news:

AElis Farma (ISIN: FR0014007ZB4 – mnemonic: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces the public availability of its half-year financial report, supplemented by Financial Markets Authority (Financial Markets Authority).

It can be consulted on the Company’s website, www.aelisfarma.comin the section Investors/Documentation/Reports.



Founded in 2013, Aelis Farma is a biopharmaceutical company developing a new class of drugs, specific inhibitors of CB signaling1 endocannabinoid system (CB) receptor1-SSi). These new molecular entities hold great potential in the treatment of many brain diseases. CC1-SSi were developed by Aelis Farma based on the discovery of a new natural brain defense mechanism made by the team of Dr. Pier Vincenzo Piazza, CEO of the Company, when he was director of the Inserm Magendie Neurocentre in Bordeaux. For these discoveries, Dr. Piazza received the Grand Prix Inserm and the Grand Prix de Neurologie from the French Academy of Sciences, which are among the most prestigious French awards in medicine and neurology.

Aelis Farma is developing two clinical-stage first-in-class drug candidates, AEF0117 and AEF0217, and has a portfolio of innovative CBs1-SSi for the treatment of other diseases associated with dysregulation of CB activity1 receiver.

AEF0117, which targets disorders due to excessive cannabis use (addiction and psychosis), showed signs of efficacy in a phase 2a clinical trial and entered a phase 2b clinical trial in the United States in Q2 2022 Aelis Farma has an exclusive option-license agreement with Indivior PLC, a leading pharmaceutical company in the treatment of addiction, for the development and commercialization of AEF0117 for disorders due to excessive cannabis use. As part of this agreement, Aelis Farma received 30 million dollars (option payment). If Indivior exercises the license option at the end of phase 2b, Aelis Farma will receive a $100 million royalty (potentially in 2024) and up to $340 million in additional payments depending on the achievement of development, regulatory and commercial stages as well as royalties on net sales of AEF0117 of between 12% and 20%.

AEF0217, which targets various cognitive disorders including those associated with Down syndrome, has completed the recruitment of its phase 1 program in healthy volunteers and will start a phase 1/2 study in subjects with Down syndrome in the fourth quarter of 2022. This compound has been the subject of an extensive preclinical proof-of-concept program using highly innovative cognitive evaluation functions. In this context, AEF0217 has demonstrated the ability to completely reverse the cognitive deficits observed in several animal models of neurodevelopmental disorders, such as Down syndrome and fragile X syndrome, as well as in models of certain cognitive deficits associated with aging.

Based in Bordeaux, within the Magendie Neurocentre, Aelis Farma has a team of 23 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui- invest and IRDI Capital Investissement.

For more information:

ISIN Code: FR0014007ZB4

Mnemo: AELIS

Compartment B of Euronext Paris


Forward-looking statements

Certain information contained in this press release is forward-looking statements and not historical data. These forward-looking statements are based on current beliefs, expectations and assumptions, including, but not limited to, assumptions about Aelis Farma’s current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements, or industry results or other events, to differ materially from those described or under -understood by these forward-looking statements. These risks and uncertainties include those set out and detailed in Chapter 3 “Risk factors” of Aelis Farma’s registration document approved by the Autorité des marchés financiers on January 14, 2022 under number I.22-003.

These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to issue updates or corrections to the forward-looking statements included in this press release to reflect any changes in expectations. or events. , conditions or circumstances on which such forward-looking statements are based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Aelis Farma. Actual results could differ materially from those described, implied or projected in the forward-looking information and statements.


Comments are closed.